Freeline Therapeutics to Host Full Year 2022 Financial Results Call

Plugin JSON Content Importer Pro not running: Check Licence! Check that a Licence is active for https://freeline.life
You might also like
Freeline Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial
Freeline to participate in Chardan’s 4th Annual Genetic Medicines Conference at the revised time of 3.45 pm EDT on 6 October
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Freeline Reports Full Year 2021 Financial Results and Business Highlights
Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
Get in touch

+44 (0)1438 906870
contact@freeline.life

Follow us on our social channels